Added to antiplatelet therapy after noncardioembolic stroke, asundexian lowered recurrent ischemic stroke from 8.4% to 6.2% with no increase in major bleeding.
Secondary prevention of ischemic stroke is crucial to reduce recurrent events and improve patient outcomes. Asundexian, an oral factor XIa inhibitor, was tested for effectiveness in combination with antiplatelet therapy versus antiplatelet therapy alone for preventing recurrent ischemic stroke. This phase 3 study explores a novel anticoagulant approach for secondary stroke prevention, which may enhance treatment strategies if shown effective. However, detailed results are needed to evaluate its clinical impact. Asundexian could be a promising option for enhancing secondary prevention in ischemic stroke patients.
Authors: Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R, Staikov I, Bae HJ, Campbell BCV, Zini A, Lee IH, Kovar M, Mikulik R, Lemmens R, Ferro JM, Robinson T, Christensen H, Ozturk S, Leker RR, Turcani P, Slowik A, Amaya P, Hoo FK, De Marchis GM, Knoflach M, Sylaja PN, Putaala J, Coutinho JM, van der Worp HB, Miglane E, Matijošaitis V, Lindgren AG, Sampaio Silva G, Sandset EC, Turuspekova ST, Amarenco P, Sheth KN, Smith EE, Eikelboom JW, Joundi RA, Schulze K, Xu L, Heenan L, Colorado P, Keller L, Muehlhofer E, Neumann C, Mundl H, Shoamanesh A, OCEANIC-STROKE Investigators
Citation: Sharma M, Dong Q, Hirano T, et al. Asundexian for Secondary Stroke Prevention. The New England journal of medicine. 2026;394(15):1467-1479. doi:10.1056/NEJMoa2513880
Article Links: PubMed · Journal / DOI
One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.